Mr. Subramaniam is the Co-Founder and Managing Partner of New Science Ventures, serving on the Board of Directors of Achronix Semiconductor Corporation, Alexar Therapeutics, Ario Pharmaceuticals, Cambridge Epigenetix, Dali Wireless, Dezima Pharma, Juventas Therapeutics, Oxyrane, Resolve Therapeutics, TigerText, Vaultive, and iCAD. Mr. Subramaniam also served on the boards of Ception (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco) and K2M (acquired by Welsh Carson).
Prior to founding NSV, Mr. Subramaniam was a director at McKinsey & Company where he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. At McKinsey, he was leader of the Strategy Practice, the Technology Practice, the Biotechnology Group and the Healthcare Practice. He also served on the firm’s Investment Committee and led its Equity Portfolio Committee.
Mr. Subramaniam holds a BTech degree from the Indian Institute of Technology and an MBA from Harvard Business School.
Achronix, BioVex, Celleration, iCAD, Juventas Therapeutics, Lightwire, MagSil, PerceptiMed, Proterixbio, Receptor Biologix, Resolve Therapeutics, RF Arrays, TigerConnect, Trellis Bioscience, Vaultive, and Vorago Technologies